Douglas Carr Sells 7,043 Shares of Century Therapeutics (NASDAQ:IPSC) Stock

Century Therapeutics, Inc. (NASDAQ:IPSC) SVP Douglas Carr sold 7,043 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $2.55, for a total value of $17,959.65. Following the completion of the sale, the senior vice president owned 507,261 shares of the company’s stock, valued at $1,293,515.55. The trade was a 1.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Douglas Carr also recently made the following trade(s):

• On Tuesday, February 3rd, Douglas Carr sold 323 shares of Century Therapeutics stock. The shares were sold at an average price of $1.82, for a total value of $587.86.

Century Therapeutics Stock Performance

NASDAQ:IPSC opened at $2.29 on Wednesday. Century Therapeutics, Inc. has a fifty-two week low of $0.34 and a fifty-two week high of $3.04. The firm has a market cap of $200.15 million, a PE ratio of -16.36 and a beta of 1.70. The business has a 50 day moving average price of $2.14 and a 200-day moving average price of $1.14.

Century Therapeutics (NASDAQ:IPSC) last issued its earnings results on Thursday, March 12th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.04. Research analysts predict that Century Therapeutics, Inc. will post -1.61 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Prudential Financial Inc. bought a new position in Century Therapeutics in the 2nd quarter worth $25,000. Qube Research & Technologies Ltd bought a new stake in shares of Century Therapeutics during the 2nd quarter valued at about $38,000. Raymond James Financial Inc. bought a new stake in shares of Century Therapeutics during the 2nd quarter valued at about $51,000. AQR Capital Management LLC increased its position in shares of Century Therapeutics by 358.9% during the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock valued at $53,000 after buying an additional 86,875 shares during the period. Finally, Bank of America Corp DE increased its position in shares of Century Therapeutics by 109.1% during the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock valued at $67,000 after buying an additional 34,466 shares during the period. 50.20% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on IPSC. Zacks Research downgraded shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 12th. Wall Street Zen raised Century Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. TD Cowen initiated coverage on Century Therapeutics in a report on Wednesday, February 25th. They set a “buy” rating on the stock. Leerink Partners set a $2.00 price target on Century Therapeutics and gave the company a “market perform” rating in a research report on Friday. Finally, Piper Sandler increased their price objective on Century Therapeutics from $2.00 to $4.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $3.80.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.